Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Nurix Therapeutics (NRIX) over the last 5 years, with Nov 2024 value amounting to $4.1 million.

  • Nurix Therapeutics' Gains from Investment Securities was N/A to $5.8 million in Q3 2025 from the same period last year, while for Aug 2025 it was $9.9 million, marking a year-over-year change of. This contributed to the annual value of $4.1 million for FY2024, which is 82.88% down from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Gains from Investment Securities is $4.1 million, which was down 82.88% from $24.0 million recorded in FY2023.
  • Nurix Therapeutics' 5-year Gains from Investment Securities high stood at $24.0 million for FY2023, and its period low was $3.4 million during FY2020.
  • Its 3-year average for Gains from Investment Securities is $11.1 million, with a median of $5.1 million in 2022.
  • In the last 5 years, Nurix Therapeutics' Gains from Investment Securities surged by 3,300.00% in 2020 and then slumped by 82.88% in 2024.
  • Nurix Therapeutics' Gains from Investment Securities (Yearly) stood at $3.4 million in 2020, then reached $5.1 million in 2022, then soared by 373.46% to $24.0 million in 2023, then plummeted by 82.88% to $4.1 million in 2024.